These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16409440)

  • 1. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
    Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
    Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F; Stewart L; Dwyer P
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J; Glavind K; Kralidis G; Wyndaele JJ
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
    Steers W; Corcos J; Foote J; Kralidis G
    BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
    Cardozo L; Dixon A
    J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
    Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
    BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S; Khullar V; Wyndaele JJ; Lheritier K;
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F; Cardozo L; Chapple C; Ridder AM;
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
    Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
    Kay GG; Wesnes KA
    BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darifenacin: in the treatment of overactive bladder.
    Croom KF; Keating GM
    Drugs Aging; 2004; 21(13):885-92; discussion 893-4. PubMed ID: 15493952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darifenacin: Pharmacology and clinical usage.
    Steers WD
    Urol Clin North Am; 2006 Nov; 33(4):475-82, viii. PubMed ID: 17011383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
    Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
    Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.